ALT - Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder

ALT Altimmune announces positive topline results from reclaim phase 2 trial of pemvidutide in alcohol use disorder Altimmune - pemvidutide meets FDA-recognized registrational endpoints in phase 2 trial - To request end-of-phase 2 meeting with FDA for pemvidutide in AUD - Pemvidutide demonstrates generally favorable tolerability profile in phase 2 trial - Pemvidutide 2.4 mg achieves significant reduction in heavy drinking days in phase 2 trial